Cancer detection using Artificial Intelligence (AI) involves leveraging advanced machine learning algorithms and techniques to identify and diagnose cancer from various medical data sources. The goal is to enhance early detection, improve diagnostic accuracy, and potentially reduce the need for invasive procedures.
Colorectal liver metastases (CRLM) are a major cause of cancer-related mortality, and reliable detection on CT remains challenging in multi-centre settings. We developed a foundation model-based AI pipeline for patient-level classification and lesion-level detection of CRLM on contrast-enhanced CT, integrating uncertainty quantification and explainability. CT data from the EuCanImage consortium (n=2437) and an external TCIA cohort (n=197) were used. Among several pretrained models, UMedPT achieved the best performance and was fine-tuned with an MLP head for classification and an FCOS-based head for lesion detection. The classification model achieved an AUC of 0.90 and a sensitivity of 0.82 on the combined test set, with a sensitivity of 0.85 on the external cohort. Excluding the most uncertain 20 percent of cases improved AUC to 0.91 and balanced accuracy to 0.86. Decision curve analysis showed clinical benefit for threshold probabilities between 0.30 and 0.40. The detection model identified 69.1 percent of lesions overall, increasing from 30 percent to 98 percent across lesion size quartiles. Grad-CAM highlighted lesion-corresponding regions in high-confidence cases. These results demonstrate that foundation model-based pipelines can support robust and interpretable CRLM detection and classification across heterogeneous CT data.
Thyroid cancer is the most common endocrine malignancy, and its incidence is rising globally. While ultrasound is the preferred imaging modality for detecting thyroid nodules, its diagnostic accuracy is often limited by challenges such as low image contrast and blurred nodule boundaries. To address these issues, we propose Nodule-DETR, a novel detection transformer (DETR) architecture designed for robust thyroid nodule detection in ultrasound images. Nodule-DETR introduces three key innovations: a Multi-Spectral Frequency-domain Channel Attention (MSFCA) module that leverages frequency analysis to enhance features of low-contrast nodules; a Hierarchical Feature Fusion (HFF) module for efficient multi-scale integration; and Multi-Scale Deformable Attention (MSDA) to flexibly capture small and irregularly shaped nodules. We conducted extensive experiments on a clinical dataset of real-world thyroid ultrasound images. The results demonstrate that Nodule-DETR achieves state-of-the-art performance, outperforming the baseline model by a significant margin of 0.149 in mAP@0.5:0.95. The superior accuracy of Nodule-DETR highlights its significant potential for clinical application as an effective tool in computer-aided thyroid diagnosis. The code of work is available at https://github.com/wjj1wjj/Nodule-DETR.
Early cancer detection relies on invasive tissue biopsies or liquid biopsies limited by biomarker dilution. In contrast, tumour-derived extracellular vesicles (EVs) carrying biomarkers like melanoma-associated antigen-A (MAGE-A) are highly concentrated in the peri-tumoral interstitial space, offering a promising near-field target. However, at micrometre scales, EV transport is governed by stochastic diffusion in a low copy number regime, increasing the risk of false negatives. We theoretically assess the feasibility of a smart-needle sensor detecting MAGE-A-positive microvesicles near a tumour. We use a hybrid framework combining particle-based Brownian dynamics (Smoldyn) to quantify stochastic arrival and false negative probabilities, and a reaction-diffusion PDE for mean concentration profiles. Formulating detection as a threshold-based binary hypothesis test, we find a maximum feasible detection radius of approximately 275 micrometers for a 6000 s sensing window. These results outline the physical limits of proximal EV-based detection and inform the design of minimally invasive peri-tumoral sensors.
Melanoma is the most lethal subtype of skin cancer, and early and accurate detection of this disease can greatly improve patients' outcomes. Although machine learning models, especially convolutional neural networks (CNNs), have shown great potential in automating melanoma classification, their diagnostic reliability still suffers due to inconsistent focus on lesion areas. In this study, we analyze the relationship between lesion attention and diagnostic performance, involving masked images, bounding box detection, and transfer learning. We used multiple explainability and sensitivity analysis approaches to investigate how well models aligned their attention with lesion areas and how this alignment correlated with precision, recall, and F1-score. Results showed that models with a higher focus on lesion areas achieved better diagnostic performance, suggesting the potential of interpretable AI in medical diagnostics. This study provides a foundation for developing more accurate and trustworthy melanoma classification models in the future.
Current histopathological grading of prostate cancer relies primarily on glandular architecture, largely overlooking the tumor microenvironment. Here, we present PROTAS, a deep learning framework that quantifies reactive stroma (RS) in routine hematoxylin and eosin (H&E) slides and links stromal morphology to underlying biology. PROTAS-defined RS is characterized by nuclear enlargement, collagen disorganization, and transcriptomic enrichment of contractile pathways. PROTAS detects RS robustly in the external Prostate, Lung, Colorectal, and Ovarian (PLCO) dataset and, using domain-adversarial training, generalizes to diagnostic biopsies. In head-to-head comparisons, PROTAS outperforms pathologists for RS detection, and spatial RS features predict biochemical recurrence independently of established prognostic variables (c-index 0.80). By capturing subtle stromal phenotypes associated with tumor progression, PROTAS provides an interpretable, scalable biomarker to refine risk stratification.
Multimodal Large Language Models (LLMs) introduce an emerging paradigm for medical imaging by interpreting scans through the lens of extensive clinical knowledge, offering a transformative approach to disease classification. This study presents a critical comparison between two fundamentally different AI architectures: the specialized open-source agent MedGemma and the proprietary large multimodal model GPT-4 for diagnosing six different diseases. The MedGemma-4b-it model, fine-tuned using Low-Rank Adaptation (LoRA), demonstrated superior diagnostic capability by achieving a mean test accuracy of 80.37% compared to 69.58% for the untuned GPT-4. Furthermore, MedGemma exhibited notably higher sensitivity in high-stakes clinical tasks, such as cancer and pneumonia detection. Quantitative analysis via confusion matrices and classification reports provides comprehensive insights into model performance across all categories. These results emphasize that domain-specific fine-tuning is essential for minimizing hallucinations in clinical implementation, positioning MedGemma as a sophisticated tool for complex, evidence-based medical reasoning.
Accurate detection of ultrasound nodules is essential for the early diagnosis and treatment of thyroid and breast cancers. However, this task remains challenging due to irregular nodule shapes, indistinct boundaries, substantial scale variations, and the presence of speckle noise that degrades structural visibility. To address these challenges, we propose a prior-guided DETR framework specifically designed for ultrasound nodule detection. Instead of relying on purely data-driven feature learning, the proposed framework progressively incorporates different prior knowledge at multiple stages of the network. First, a Spatially-adaptive Deformable FFN with Prior Regularization (SDFPR) is embedded into the CNN backbone to inject geometric priors into deformable sampling, stabilizing feature extraction for irregular and blurred nodules. Second, a Multi-scale Spatial-Frequency Feature Mixer (MSFFM) is designed to extract multi-scale structural priors, where spatial-domain processing emphasizes contour continuity and boundary cues, while frequency-domain modeling captures global morphology and suppresses speckle noise. Furthermore, a Dense Feature Interaction (DFI) mechanism propagates and exploits these prior-modulated features across all encoder layers, enabling the decoder to enhance query refinement under consistent geometric and structural guidance. Experiments conducted on two clinically collected thyroid ultrasound datasets (Thyroid I and Thyroid II) and two public benchmarks (TN3K and BUSI) for thyroid and breast nodules demonstrate that the proposed method achieves superior accuracy compared with 18 detection methods, particularly in detecting morphologically complex nodules.The source code is publicly available at https://github.com/wjj1wjj/Ultrasound-DETR.




Deep neural networks are starting to show their worth in critical applications such as assisted cancer diagnosis. However, for their outputs to get accepted in practice, the results they provide should be explainable in a way easily understood by pathologists. A well-known and widely used explanation technique is occlusion, which, however, can take a long time to compute, thus slowing the development and interaction with pathologists. In this work, we set out to find a faster replacement for occlusion in a successful system for detecting prostate cancer. Since there is no established framework for comparing the performance of various explanation methods, we first identified suitable comparison criteria and selected corresponding metrics. Based on the results, we were able to choose a different explanation method, which cut the previously required explanation time at least by a factor of 10, without any negative impact on the quality of outputs. This speedup enables rapid iteration in model development and debugging and brings us closer to adopting AI-assisted prostate cancer detection in clinical settings. We propose that our approach to finding the replacement for occlusion can be used to evaluate candidate methods in other related applications.
Modern clinical decision support systems can concurrently serve multiple, independent medical imaging institutions, but their predictive performance may degrade across sites due to variations in patient populations, imaging hardware, and acquisition protocols. Continuous surveillance of predictive model outputs offers a safe and reliable approach for identifying such distributional shifts without ground truth labels. However, most existing methods rely on centralized monitoring of aggregated predictions, overlooking site-specific drift dynamics. We propose an agent-based framework for detecting drift and assessing its severity in multisite clinical AI systems. To evaluate its effectiveness, we simulate a multi-center environment for output-based drift detection, assigning each site a drift monitoring agent that performs batch-wise comparisons of model outputs against a reference distribution. We analyse several multi-center monitoring schemes, that differ in how the reference is obtained (site-specific, global, production-only and adaptive), alongside a centralized baseline. Results on real-world breast cancer imaging data using a pathological complete response prediction model shows that all multi-center schemes outperform centralized monitoring, with F1-score improvements up to 10.3% in drift detection. In the absence of site-specific references, the adaptive scheme performs best, with F1-scores of 74.3% for drift detection and 83.7% for drift severity classification. These findings suggest that adaptive, site-aware agent-based drift monitoring can enhance reliability of multisite clinical decision support systems.
The popular use of histopathology images, such as hematoxylin and eosin (H&E), has proven to be useful in detecting tumors. However, moving such cancer cases forward for treatment requires accurate on the amount of the human epidermal growth factor receptor 2 (HER2) protein expression. Predicting both the lower and higher levels of HER2 can be challenging. Moreover, jointly analyzing H&E and immunohistochemistry (IHC) stained images for HER2 scoring is difficult. Although several deep learning methods have been investigated to address the challenge of HER2 scoring, they suffer from providing a pixel-level localization of HER2 status. In this study, we propose a single end-to-end pipeline using a system of vision transformers with HER2 status scoring on whole slide images of WSIs. The method includes patch-wise processing of H&E WSIs for tumor localization. A novel mapping function is proposed to correspondingly identify correlated IHC WSIs regions with malignant regions on H&E. A clinically inspired HER2 scoring mechanism is embedded in the pipeline and allows for automatic pixel-level annotation of 4-way HER2 scoring (0, 1+, 2+, and 3+). Also, the proposed method accurately returns HER2-negative and HER2-positive. Privately curated datasets were collaboratively extracted from 13 different cases of WSIs of H&E and IHC. A thorough experiment is conducted on the proposed method. Results obtained showed a good classification accuracy during tumor localization. Also, a classification accuracy of 0.94 and a specificity of 0.933 were returned for the prediction of HER2 status, scoring in the 4-way methods. The applicability of the proposed pipeline was investigated using WSIs patches as comparable to human pathologists. Findings from the study showed the usability of jointly evaluated H&E and IHC images on end-to-end ViTs-based models for HER2 scoring